STAIDSON (BEIJING) BIOPHARMACEUTICALS CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.93 CNY | +0.68% |
|
-0.17% | -41.63% |
| Sales 2022 | 549M 75.77M | Sales 2023 | 364M 50.27M | Capitalization | 4.85B 670M |
|---|---|---|---|---|---|
| Net income 2022 | -197M -27.19M | Net income 2023 | -399M -55.07M | EV / Sales 2022 | 11.2 x |
| Net cash position 2022 | 259M 35.77M | Net cash position 2023 | 44.23M 6.1M | EV / Sales 2023 | 13.2 x |
| P/E ratio 2022 |
-33.2
x | P/E ratio 2023 |
-12.1
x | Employees | 555 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 25.45% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.68% | ||
| 1 week | -0.17% | ||
| Current month | -12.28% | ||
| 1 month | -19.43% | ||
| 3 months | -29.49% | ||
| 6 months | -34.76% | ||
| Current year | -41.63% |
1 week
5.51
5.96
1 month
5.447.05
Current year
5.4410.38
1 year
5.4413.33
3 years
5.4429.85
5 years
5.4429.85
10 years
5.4445.37
| Managers | Title | Age | Since |
|---|---|---|---|
Chao Wang
CEO | Chief Executive Officer | 42 | 11-06-30 |
Shi Cheng Li
DFI | Director of Finance/CFO | 42 | 20-08-25 |
Zhi Wen Zhou
PSD | President | 59 | 01-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Hong Shan Zhang
CHM | Chairman | 60 | 01-12-31 |
Zhi Wen Zhou
CHM | Chairman | 59 | 01-12-31 |
Tao Li
BRD | Director/Board Member | 61 | 07-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 34 M€ | +2.35% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-24 | 5.93 | +0.68% | 3,745,100 |
| 24-04-23 | 5.89 | +2.43% | 5,902,655 |
| 24-04-22 | 5.75 | +1.77% | 4,771,600 |
| 24-04-19 | 5.65 | -3.09% | 5,105,590 |
| 24-04-18 | 5.83 | -1.85% | 4,789,253 |
End-of-day quote Shenzhen S.E., April 23, 2024
More quotes
Staidson (Beijing) Biopharmaceuticals Co., Ltd. is a China-based company principally engaged in the research, development, manufacture and sales of innovative therapeutic medicine with independent intellectual property rights including protein medicine, genetic medicine and chemical medicine, among others. The Companyâs products include mouse nerve growth factor for injection, which are applied in the neuroprotection and treatment of nerve injuries, as well as polyethylene glycol electrolyte powders, which are applied in the bowel cleansing and treatment of constipation. The Company mainly distributes its products in domestic market.
Sector
Pharmaceuticals
Calendar
2024-04-24
- Q1 2024 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| -41.63% | 391M | |
| -2.86% | 87.31B | |
| +3.95% | 40.86B | |
| -21.94% | 29.36B | |
| +56.53% | 24.49B | |
| -5.41% | 17.31B | |
| -44.23% | 11.26B | |
| -17.60% | 11.62B | |
| -13.96% | 11.31B | |
| +6.44% | 8.31B |
- Stock Market
- Equities
- 300204 Stock
